IART Integra LifeSciences Holdings Corporation
USHealthcareAs of 2026-07-10 16:00
Why IART matters now
Integra LifeSciences Holdings Corporation (IART) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.79 with +2.18% on the session and $1.46B in market capitalization; recent performance reads 1-month +22.25% and YTD +41.55%.
The latest financial table shown here is Q1 2026, with revenue of $391.9M, net income of $-4.6M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.7%.
The latest indexable market news headline is "Here's Why Integra LifeSciences (IART) is a Strong Value Stock" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $18.50; recent insider activity includes BRADLEY KEITH filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.30
P/S
0.83
EV/EBITDA
-10.96
DCF Value
$23.29
FCF Yield
-0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.2%
Operating Margin
7.5%
Net Margin
-30.1%
ROE
-47.6%
ROA
-13.9%
ROIC
3.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $391.9M | $-4.6M | $-0.06 |
| Q4 2025 | $434.9M | $-1.7M | $-0.02 |
| FY 2025 | $1.64B | $-516.5M | $-6.73 |
| Q3 2025 | $402.1M | $-5.4M | $-0.07 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$18.50
Target (Median)
$18.50
Target Range
$12.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.25
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.